Madrigal Stock Soars 7%, Adding $650 Million After A Month-Long Slide

The rebound contrasts with a sustained retreat in shares, even as Rezdiffra sales grew and Madrigal posted its first profitable quarter.

Share
Madrigal Stock Soars 7%, Adding $650 Million After A Month-Long Slide

Madrigal Pharmaceuticals, which develops treatments for MASH, a serious liver disease, soared 7.00% to $427.60 in Monday trading, as of 12:06 PM ET, adding $650 million in market value. The rebound came even as Schall, Brown & Schwartz announced Monday that it was investigating possible violations of securities laws involving allegedly misleading statements or omissions.

A Rebound After The Retreat

Madrigal was on pace for its biggest one-day gain since June 3 in Monday trading, as of 12:06 PM ET. Its market value stood at $9.93 billion at that same Monday trading checkpoint, with shares still 30% below their 52-week high.

At Friday's close, the stock was down 31% for the year, compared with an 8% gain for the S&P 500. Madrigal had also lost 20% over the previous month.

Baker Bros.' amended SEC ownership filing, made public after Friday's close, showed that Baker Brothers Life Sciences bought 91,806 shares across Wednesday and Friday. The investor reported about 10% beneficial ownership, with exercisable warrants and options included in both its holdings and the share base used for that percentage, and described the securities as investments.

Rezdiffra Delivers The First Profit

The share-price retreat contrasted with Madrigal's third-quarter results. Revenue rose 50.1% from a year earlier to $431.3 million, according to its quarterly SEC filing. Net income was $55.4 million, and the operating margin was 13%.

Madrigal's Tuesday earnings release called it the company's first profitable quarter. Rezdiffra net sales reached $1.1 billion for the first nine months, and more than 55,850 patients were taking the drug as of September 30, nearly double the year-earlier count.

Rezdiffra is Madrigal's only approved product: a daily pill for adults with MASH and moderate to advanced liver scarring. MASH can progress to cirrhosis, liver failure and liver cancer. Sales began in the United States in April 2024 and in Germany in September 2025; European approval covers the European Union's 27 members, Iceland, Liechtenstein and Norway.

Madrigal reported $958.4 million in Rezdiffra product revenue for 2025. Its U.S. sales effort targets liver and digestive specialists and, starting in the fourth quarter of 2025, select endocrinologists.

The Push Into Advanced Disease

Madrigal expects late-2027 results from its ongoing late-stage trial in patients with advanced liver disease. It also plans another late-stage outcomes trial, expected to enroll more than 2,000 patients with well-compensated MASH cirrhosis, with initiation expected in the first half of 2027, subject to regulatory discussions.

Bill Sibold, Madrigal's chief executive officer, said in Tuesday's release: “Our objective in F4c is clear: be first and best.” F4c refers to well-compensated cirrhosis, the advanced stage targeted by those trials.

Madrigal held $961.8 million in cash, cash equivalents, restricted cash and marketable securities as of September 30. Beyond Rezdiffra, it holds licenses to MASH drug candidates including an oral GLP-1 drug, ervogastat and six siRNA programs.

Sources

More on Madrigal Pharmaceuticals

All Madrigal Pharmaceuticals (MDGL) coverage →